Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 10c

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of $0.09, $0.10 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $67.14 million.

Sagent Pharmaceuticals, Inc. sees FY2014 revenue of $270-290 million, versus the consensus of $279.07 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c
• Borr Drilling (BORR) Misses Q2 EPS by 69c